close

Agreements

1 243 244 245 246
Number of results: 4911

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-01-11 Biofocus, a Galapagos Company (UK - Belgium) Ono Pharmaceutical (Japan) novel targets in the field of autoimmune disease

Autoimmune diseases

R&D Autoimmune diseases
2011-01-11 Alacris Theranostics (Germany) Qiagen (The Netherlands) stake in Alacris Theranostics
2011-01-10 Biocartis (Belgium) Janssen Pharmaceutica NV (J&J - USA) molecular diagnostic tests

development

Infectious diseases - CNS diseases Development agreement
2011-01-09 Silence Therapeutics (UK) miRagen Therapeutics (USA) use of Silence’s proprietary DBTC delivery system for miRagen’s novel microRNA- (miRNA-) based therapeutics undisclosed

R&D

R&D agreement
2011-01-06 Cell Medica (UK) Center for Cell and Gene Therapy (CAGT), Baylor College of Medicine (Houston, Texas - USA) cell-based treatment for cancers associated with the oncogenic Epstein Barr virus (EBV) EBV-associated lymphoma and nasopharyngeal carcinoma (NPC)

R&D
licensing
commercialisation

Cancer - Oncology R&D agreement
2011-01-06 Spirogen (UK) - Genentech a member of the Roche Group (USA-Switzerland) antibody drug conjugates (ADCs) as potential anticancer agents cancer

R&D
licensing

Cancer - Oncology Licensing agreement
2011-01-05 arGEN-X (The Netherlands) Eli Lilly (USA) therapeutic antibodies

R&D

Cancer - Oncology R&D agreement
2011-01-05 Transgene (France) Beckman Coulter (USA) companion test to measure the level of activated Natural Killer (“aNK”) cells in order to select patients to be treated with TG4010 (MVA-MUC1-IL2 immunotherapy candidate, is about to enter into a pivotalPhase IIb/III clinical trial for the treatment of Non-Small Cell Lung Cancer) non small cell lung cancer

R&D
Development

Cancer Oncology R&D agreement
2011-01-05 Selexis (Switzerland) Neogenix Oncology (USA) production cell line expressing Neogenix NPC-1C

licensing
commercialisation

Licensing agreement
2011-01-05 to-BBB (The Netherlands) Synageva BioPharma (USA) transporting therapeutic proteins across the blood-brain barrier into the central nervous system

R&D

Rare diseases R&D agreement
2011-01-04 Argenta (Galapagos subsidiary – UK Belgium) Dr. Reddy's Laboratories (India) pain-inflammation

development
commercialisation

CNS diseases - Inflammatory diseases Development agreement
2011-01-04 Kinaxo Biotechnology (Germany) AstraZeneca (UK) drug targets

R&D

Cancer Oncology R&D agreement
2011-01-04 Santaris Pharma (Denmark) Pfizer (USA - NY) RNA-targeted medicines using Santaris Pharma A/S Locked Nucleic Acid (LNA) Drug Platform.

R&D
Commercialisation

R&D agreement
2011-01-04 Servier (France) Xoma (USA - CA) gevokizumab (Xoma 052) Behcet\'s uveitis, inflammatory diseases, cancer Cancer - Oncology - Inflammatory diseases - Rare diseases Development agreement
2011-01-03 Mercator Therapeutics (USA) Pepscan Therapeutics (The Netherlands) optimization of homing peptides tumors

R&D

Cancer - Oncology R&D agreement
2010-01-10 Bind Biosciences (USA - MA)

nomination

Nomination
2010-01-06 Amsterdam Molecular Therapeutics (The Netherlands) - consortium led by Institut Pasteur (France) adeno-associated viral 5 (AAV5) gene therapy Sanfilippo B (rare autosomal recessive lysosomal storage disease, which manifests in young children)

Development
Manufacturing
Production

Rare diseases Development agreement
0201-10-06 Horizon Discovery (UK) Haplogen Genomics (Austria) CRISPR/Cas9 human haploid cell line generation service and human haploid knock-out cell lines catalog

distribution

Technology - Services Distribution agreement
0000-00-00 Ipsen (France) Oncodesign (France) new therapeutic agents against the LRRK2 Parkinson's disease target Parkinson's disease R&D - research Neurodegenerative diseases - CNS diseases Termination of an agreement
0000-00-00 ViiV Healthcare (UK - USA) the Medicines Patent Pool Tivicay® (dolutegravir) HIV1-infection

collaboration

Infectious diseases Collaboration agreement